Effect of acute and prolonged mineralocorticoid receptor blockade on spontaneous and stimulated hypothalamic-pituitary-adrenal axis in humans

European Journal of Endocrinology

Volumn 162, Issue 6, 2010, Pages 1067-1074

  Berardelli, Rita ^a   Karamouzis, Ioannis ^a   Marinazzo, Elisa ^a   Prats, Elisa ^a   Picu, Andreea ^a   Giordano, Roberta ^b   Ghigo, Ezio ^a   Arvat, Emanuela ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANRENOIC ACID; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR; PLACEBO; PRASTERONE;

ABSENCE OF SIDE EFFECTS; ADULT; ANDROGEN BLOOD LEVEL; ANDROGEN RELEASE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; FEMALE; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NORMAL HUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RECEPTOR BLOCKING; TREATMENT DURATION;

ADRENAL GLANDS; ADRENOCORTICOTROPIC HORMONE; ADULT; ANALYSIS OF VARIANCE; CANRENOATE POTASSIUM; CORTICOTROPIN-RELEASING HORMONE; DEHYDROEPIANDROSTERONE; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; HYPOTHALAMUS; PITUITARY GLAND; PITUITARY-ADRENAL SYSTEM; RECEPTORS, MINERALOCORTICOID;

EID: 77952740545     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-1076     Document Type: Article

References (34)

1. Gaillard RC & Al-Damluji S. Stress and the pituitary-adrenal axis. Bailliere's Clinical Endocrinology and Metabolism 1987 1 319-354.
2. Orth DN. Corticotropin-releasing hormone in humans. Endocrine Reviews 1992 13 164-191.
3. Jacobson L & Sapolsky R. The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocrine Reviews 1991 12 118-134.
4. De Kloet ER, Vreugdehil E, Oitzl MS & Joels M. Brain corticosteroid receptor balance in health and disease. Endocrine Reviews 1998 19 269-301.
5. Arvat E, Maccagno B, Giordano R, Pellegrino M, Broglio F, Gianotti L, Maccario M, Camanni F & Ghigo E. Mineralocorticoid receptor blockade by canrenoate increases both spontaneous and stimulated adrenal function in humans. Journal of Clinical Endocrinology and Metabolism 2001 86 3176-3181.
6. Grottoli S, Giordano R, Maccagno B, Pellegrino M, Ghigo E & Arvat E. The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus-pituitary-adrenal axis is abolished by alprazolam, a benzodiazepine, in humans. Journal of Clinical Endocrinology and Metabolism 2002 87 4616-4620.
7. Funder JW. Glucocorticoid and mineralcorticoid receptors: biology and clinical relevance. Annual Review of Medicine 1997 48 231-240.
8. Ribeiro RC, Kushner PJ & Baxter JD. The nuclear hormone receptor gene superfamily. Annual Review of Medicine 1995 46 443-453.
9. Grossmann C, Scholz T, Rochel M, Bumke-Vogt C, Oelkers W, Pfeiffer AF, Diederich S & Bahr V. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. European Journal of Endocrinology 2004 151 397-406.
10. Reul JM & de Kloet ER. Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 1985 117 2505-2511.
11. Reul JM, Gesing A, Droste S, Stec IS, Weber A, Bachmann C, Bilang-Bleuel A, Holsboer F & Linthorst AC. The brain mineralocorticoid receptor: greedy for ligand, mysterious in function. European Journal of Pharmacology 2000 405 235-249.
12. Dallman MF, Levin N, Cascio CS, Akana SF, Jacobson L & Kuhn RW. Pharmacological evidence that the inhibition of diurnal adrenocorticotropin secretion by corticosteroids is mediated via type I corticosterone-preferring receptors. Endocrinology 1989 124 2844-2850.
13. Spencer RL, Miller AH, Moday H, Stein M & McEwen BS. Diurnal differences in basal and acute stress levels of type I and type II adrenal steroid receptor activation in neural and immune tissues. Endocrinology 1993 133 1941-1950. (Pubitemid 23324694)
14. Kalman BA & Spencer RL. Rapid corticosteroid-dependent regulation of mineralocorticoid receptor protein expression in rat brain. Endocrinology 2002 143 4184-4195.
15. Otte C, Jahn H, Yassouridis A, Arlt J, Stober N, Maass P, Wiedemann K & Kellner M. The mineralcorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone. Life Sciences 2003 73 1835-1845. (Pubitemid 36897743)
16. Otte C, Yassouridis A, Jahn H, Maass P, Stober N, Wiedemann K & Kellner M. Mineralocorticoid receptormediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. Journal of Gerontology: Biological Sciences 2003 58 900-905. (Pubitemid 37296683)
17. Herman JP, Prewitt CM & Cullinan WE. Neuronal circuit regulation of the hypothalamo-pituitary-adrenocortical stress axis. Critical Reviews in Neurobiology 1996 10 371-394. (Pubitemid 27036104)
18. Herman JP, Watson SJ & Spencer R. Defense of adrenocorticosteroid receptor expression in rat hippocampus: effects of stress and strain. Endocrinology 1999 140 3981-3991. (Pubitemid 30647092)
19. Swanson LW, Sawchenko PE, Lind RW & Rho JH. The CRH motoneuron: differential peptide regulation in neurons with possible synaptic, paracrine, and endocrine outputs. Annals of the New York Academy of Sciences 1987 512 12-23.
20. Swanson LW. Biochemical switching in hypothalamic circuits mediating responses to stress. Progress in Brain Research 1991 87 181-200.
21. Oitzl MS, van Haarst AD, SutantoW& de Kloet ER. Corticosterone, brain mineralocorticoid receptor (MRs) and the activity of the hypothalamic- pituitary-adrenal (HPA) axis: the Lewis rat as an example of increased central MR capacity and a hyporesponsive HPA axis. Psychoneuroendocrinology 1995 20 655-675.
22. Ratka A, Sutanto W, Bloemers M & de Kloet ER. On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation. Journal of Neuroendocrinology 1989 50 117-123. (Pubitemid 19179834)
23. Deuschle M, Weber B, Colla M, Muller M, Kniest A & Heuser I. Mineralocorticoid receptor also modulates basal activity of hypothalamus- pituitary-adrenocortical system in humans. Journal of Neuroendocrinology 1998 68 355-360. (Pubitemid 28526313)
24. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ & Akil H. The role of mineralcorticoid receptors in hypothalamo-pituitary- adrenocortical axis regulation in humans. Journal of Clinical Endocrinology and Metabolism 1998 83 3339-3345. (Pubitemid 28500982)
25. Born J, DeKloet ER, Wenz H, Kern W & Fehm HL. Gluco- and antimineralocorticoid effects on human sleep: a role of central corticosteroid receptors. American Journal of Physiology 1991 260 183-188.
26. Wellhoener P, Born J, Fehm HL & Dodt C. Elevated resting and exercise-induced cortisol levels after mineralocorticoid receptor blockade with canrenoate in healthy humans. Journal of Clinical Endocrinology and Metabolism 2004 89 5048-5052. (Pubitemid 39391447)
27. Rothuizen J, Reul JM, van Sluijs FJ, Mol JA, Rijnberk A & De Kloet ER. Increased neuroendocrine reactivity and decreased brain mineralocorticoid receptor-binding capacity in aged dogs. Endocrinology 1993 132 161-182.
28. Giordano R, Bo M, Pellegrino M, Vezzari M, Baldi M, Picu A, Balbo M, Bonelli L, Migliaretti G, Ghigo E & Arvat E. Hypothalamus-pituitary-adrenal hyperactivity in human aging is partially refractory to stimulation by mineralcorticoid receptor blockade. Journal of Clinical Endocrinology and Metabolism 2005 90 5656-5662. (Pubitemid 41415472)
29. Dodt C, Kern W, Fehm HL & Born J. Antimineralocorticoid canrenoate enhances secretory activity of the hypothalamus- pituitary-adrenocortical (HPA) axis in humans. Neuroendocrinology 1993 58 570-574. (Pubitemid 23343940)
30. Funder JW, Carey RM, Fardella C, Gomez-Sanchez GE, Mantero F, Stowasser M, Young FW Jr & Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2008 93 3266-3281.
31. Buckley TM, Mullen BC & Schatzberg AF. The acute effects of a mineralocorticoid receptor (MR) agonist on nocturnal hypothalamic- adrenal-pituitary (HPA) axis activity in healthy controls. Psychoneuroendocrinology 2007 32 859-864
32. Giordano R, Pellegrino M, Picu A, Bonelli L, Oleandri SE, Pellissetto C, Limone P, Migliaretti G, Maccario M, Ghigo E & Arvat E. Primary hyperaldosteronism is associated with derangement in the regulation of the hypothalamus-pituitary-adrenal axis in humans. Journal of Endocrinological Investigation 2007 30 558-563. (Pubitemid 47577808)
33. Cheng SC, Suzuki K, Sadee W & Harding BW. Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria. Endocrinology 1976 99 1097-1106.
34. Patchev VK, Brady LS, Karl M & Chrousos GP. Regulation of HSP90 and corticosteroid receptor mRNA by corticosterone levels in vivo. Molecular and Cellular Endocrinology 1994 103 57-64. (Pubitemid 24195545)